At the 64th Annual Meeting of the American Society of Hematology (ASH 2022), Ghayas C. Issa, MD, an expert on AML, talked about the first phase of the AUGMENT-101 trial. The study looked at how safe and effective Revumenib was as a single drug for people with relapsed or resistant acute leukemia with KMT2Ar (MLLr) or NPM1 mutations.
Currently, there are no approved targeted treatments for NPM1-mutated acute myeloid leukemia (which is found in 30% of people with newly diagnosed AML) or mixed lineage leukemia-rearranged (MLLr, currently called KMT2Ar, 10% of AML), a type of acute leukemia that often doesn't respond to standard treatments and is caused by spontaneous translocations at the MLL1 gene. Revumenib stops the mechanisms of both types of AML, NMP1-mutated AML and KMT2Ar (MLLr) AML.
Revumenib (also called SNDX-5613) is a powerful and selective KMT2Ar-Menin inhibitor that stops the interaction of KMT2Ar proteins that strongly bind to the protein Menin. This stops the abnormal gene expression and kills the AML cells.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Did you know you can learn more about clinical trials in HealthTree? Visit our AML Clinical Trial Finder.
If you need assistance finding or joining clinical trials, please contact our Patient Navigator support team at 1-800-930-5159 or at support@healthtree.org.
about the author
Arturo Hurtado
Arturo Hurtado is an International Medical Graduate who joined HealthTree in 2020 as part of the Patient Experience team. He helps patients understand their disease panorama and navigate their AML through the tools and resources that HealthTree provides. He is an enthusiastic photographer, tech nerd, and aspiring food explorer who loves to travel and find new exciting experiences.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.